[go: up one dir, main page]

WO2008034623A3 - Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases - Google Patents

Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases Download PDF

Info

Publication number
WO2008034623A3
WO2008034623A3 PCT/EP2007/008215 EP2007008215W WO2008034623A3 WO 2008034623 A3 WO2008034623 A3 WO 2008034623A3 EP 2007008215 W EP2007008215 W EP 2007008215W WO 2008034623 A3 WO2008034623 A3 WO 2008034623A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
diagnosis
treatment
medicament
ischaemic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/008215
Other languages
German (de)
French (fr)
Other versions
WO2008034623A2 (en
Inventor
Holger Eltzschig
Tobias Eckle
Almut Grenz
Melanie Hart
Hartmut Osswald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of WO2008034623A2 publication Critical patent/WO2008034623A2/en
Publication of WO2008034623A3 publication Critical patent/WO2008034623A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to nucleotide-phosphohydrolase and adenosine-A2B receptor agonists used as medicaments for the prophylaxis, treatment or diagnosis of ischaemic diseases, to methods for diagnosing a predisposition to an ischaemic disease or for diagnosing the disease in a living being and to a pharmaceutical or diagnostic composition.
PCT/EP2007/008215 2006-09-20 2007-09-20 Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases Ceased WO2008034623A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006046410.9 2006-09-20
DE102006046410A DE102006046410A1 (en) 2006-09-20 2006-09-20 Medicaments for the prophylaxis or treatment or diagnosis of ischemic diseases

Publications (2)

Publication Number Publication Date
WO2008034623A2 WO2008034623A2 (en) 2008-03-27
WO2008034623A3 true WO2008034623A3 (en) 2008-05-08

Family

ID=39092850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/008215 Ceased WO2008034623A2 (en) 2006-09-20 2007-09-20 Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases

Country Status (2)

Country Link
DE (1) DE102006046410A1 (en)
WO (1) WO2008034623A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU839495A1 (en) * 1979-04-03 1981-06-23 Винницкий Медицинский Институт Им.H.И.Пирогова Method of differential diagnosis of heart rheumatic disease and heart ischemic disease complicated with cardiac fibrillation
WO2001011949A1 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Cd39/ecto-adpase for treatment of thrombotic and ischemic disorders
WO2003105666A2 (en) * 2002-06-12 2003-12-24 Biogen, Inc. Method of treating ischemia reperfusion injury using adenosine receptor antagonists
WO2005040155A1 (en) * 2003-10-02 2005-05-06 Almirall Prodesfarma, S.A. Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023459A1 (en) * 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
DE19947154A1 (en) * 1999-10-01 2001-10-04 Bayer Ag Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
US7390485B2 (en) * 2004-02-27 2008-06-24 Apt Therapeutics, Inc. Design and therapeutic use of adpase enhanced apyrases
ES2732071T3 (en) * 2005-04-01 2019-11-20 Univ Florida Biomarkers of liver lesions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU839495A1 (en) * 1979-04-03 1981-06-23 Винницкий Медицинский Институт Им.H.И.Пирогова Method of differential diagnosis of heart rheumatic disease and heart ischemic disease complicated with cardiac fibrillation
WO2001011949A1 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Cd39/ecto-adpase for treatment of thrombotic and ischemic disorders
WO2003105666A2 (en) * 2002-06-12 2003-12-24 Biogen, Inc. Method of treating ischemia reperfusion injury using adenosine receptor antagonists
WO2005040155A1 (en) * 2003-10-02 2005-05-06 Almirall Prodesfarma, S.A. Pyrimidin-2-amine derivates and their use as a2b adenosine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUCKELBERGER O ET AL: "BENEFICIAL EFFECTS OF CD39/ECTO-NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE-I IN MURINE INTESTINAL ISCHEMIA-REPERFUSION INJURY", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 91, no. 3, 2004, pages 576 - 586, XP008034526, ISSN: 0340-6245 *

Also Published As

Publication number Publication date
DE102006046410A1 (en) 2008-03-27
WO2008034623A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
WO2008096012A3 (en) Multimeric conjugate
PH12013500892B1 (en) Composition for use in the prevention and\or treatment of skin conditions and skin diseases
WO2008137758A3 (en) Amino acid lipids and uses thereof
BRPI0909894A2 (en) "method of reducing the rate of progression of parkinson's disease in an early stage parkinson's disease patient, method of reducing the rate of progression of parkinson's disease, method of delaying the need for symptomatic antiparkinsonian therapy in a patient of early-stage parkinson's, risk-reduction method for a parkinson's disease patient requiring antiparkinsonian therapy, early-stage parkinson's disease reduction method, functional-decline method for a patient with Parkinson's disease, a patient's treatment method that displays early signs of parkinson's disease, fatigue reduction method in an early-stage parkinson's disease patient, method of reducing the rate of clinical progression, and treatment of symptoms of parkinsonian disease. parkinson in a patient with parkinson's disease, rasagiline or a pharmaceutically acceptable salt of rasagiline, pharmaceutical composition.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
WO2007106577A3 (en) Gelsolin in the treatment and diagnosis of neurological disease
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
BRPI0806392A8 (en) use of aclidinium, aclidinium, treatment or prevention method and pharmaceutical composition
IL197575A (en) Method for the expansion of adult stem cells from blood, use thereof for the preparation of medicament for the treatment of lesions and pharmaceutical composition comprising said adult stem cells
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
WO2010064248A3 (en) Methods of diagnosing and treating motor neuron diseases
WO2010004283A3 (en) Sulfonylurea receptor and means for treating ischaemia
EP2305316A3 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2007120252A3 (en) Soluble human m-csf receptor and uses thereof
EP2005194A4 (en) Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders
WO2009004914A1 (en) Pet probe having alkoxy group substituted by fluorine and hydroxy group

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818305

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07818305

Country of ref document: EP

Kind code of ref document: A2